Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 4 , Pages 641-655 , December 2007

Potential therapies based on antidiabetic peptides

  • Sudhesh Kumar, MD, FRCP (Professor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 024 765 74665; fax: +44 024 765 74871.

References 

  1. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425–432
  2. Muoio DM, Lynis Dohm G. Peripheral metabolic actions of leptin. Best practice & research. 2002;16(4):653–666
  3. Barr VA, Lane K, Taylor SI. Subcellular localization and internalization of the four human leptin receptor isoforms. The Journal of biological chemistry. 1999;274(30):21416–21424
  4. Ghilardi N, Ziegler S, Wiestner A, et al. Defective STAT signaling by the leptin receptor in diabetic mice. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(13):6231–6235
  5. Fruhbeck G. A heliocentric view of leptin. The Proceedings of the Nutrition Society. 2001;60(3):301–318
  6. Lammert A, Kiess W, Bottner A, et al. Soluble leptin receptor represents the main leptin binding activity in human blood. Biochemical and biophysical research communications. 2001;283(4):982–988
  7. Sinha MK, Opentanova I, Ohannesian JP, et al. Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. The Journal of clinical investigation. 1996;98(6):1277–1282
  8. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. The New England journal of medicine. 1996;334(5):292–295
  9. Heptulla R, Smitten A, Teague B, et al. Temporal patterns of circulating leptin levels in lean and obese adolescents: relationships to insulin, growth hormone, and free fatty acids rhythmicity. The Journal of clinical endocrinology and metabolism. 2001;86(1):90–96
  10. Havel PJ, Kasim-Karakas S, Dubuc GR, et al. Gender differences in plasma leptin concentrations. Nature medicine. 1996;2(9):949–950
  11. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin–the classical, resistin–the controversical, adiponectin–the promising, and more to come. Best Pract Res Clin Endocrinol Metab. 2005;19(4):525–546
  12. Margetic S, Gazzola C, Pegg GG, et al. Leptin: a review of its peripheral actions and interactions. International journal of obesity and related metabolic disorders. 2002;26(11):1407–1433
  13. Dal Farra C, Zsurger N, Vincent JP, et al. Binding of a pure 125I-monoiodoleptin analog to mouse tissues: a developmental study. Peptides. 2000;21(4):577–587
  14. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999;282(16):1568–1575
  15. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. The Journal of clinical investigation. 2002;110(8):1093–1103
  16. Williamson DA, Ravussin E, Wong ML, et al. Microanalysis of eating behavior of three leptin deficient adults treated with leptin therapy. Appetite. 2005;45(1):75–80
  17. Wolk R, Berger P, Lennon RJ, et al. Plasma leptin and prognosis in patients with established coronary atherosclerosis. Journal of the American College of Cardiology. 2004;44(9):1819–1824
  18. Reilly MP, Iqbal N, Schutta M, et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. The Journal of clinical endocrinology and metabolism. 2004;89(8):3872–3878
  19. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;271(18):10697–10703
  20. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270(45):26746–26749
  21. Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996;221(2):286–289
  22. Nakano Y, Tobe T, Choi-Miura NH, et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo). 1996;120(4):803–812
  23. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772–783
  24. Waki H, Yamauchi T, Kamon J, et al. Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology. 2005;146(2):790–796
  25. Hada Y, Yamauchi T, Waki H, et al. Selective purification and characterization of adiponectin multimer species from human plasma. Biochem Biophys Res Commun. 2007;356(2):487–493
  26. Pajvani UB, Du X, Combs TP, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem. 2003;278(11):9073–9085
  27. Waki H, Yamauchi T, Kamon J, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem. 2003;278(41):40352–40363
  28. Korner A, Wabitsch M, Seidel B, et al. Adiponectin expression in humans is dependent on differentiation of adipocytes and down-regulated by humoral serum components of high molecular weight. Biochem Biophys Res Commun. 2005;337(2):540–550
  29. Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24(1):29–33
  30. Yamamoto Y, Hirose H, Saito I, et al. Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab. 2004;89(1):87–90
  31. Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361(9353):226–228
  32. Bottner A, Kratzsch J, Muller G, et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab. 2004;89(8):4053–4061
  33. Kos K, Harte AL, da Silva NF, et al. Adiponectin and resistin in human cerebrospinal fluid and expression of adiponectin receptors in the human hypothalamus. J Clin Endocrinol Metab. 2007;
  34. Kusminski CM, McTernan PG, Schraw T, et al. Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum. Diabetologia. 2007;50(3):634–642
  35. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423(6941):762–769
  36. Kharroubi I, Rasschaert J, Eizirik DL, et al. Expression of adiponectin receptors in pancreatic beta cells. Biochem Biophys Res Commun. 2003;312(4):1118–1122
  37. Chinetti G, Zawadski C, Fruchart JC, et al. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem Biophys Res Commun. 2004;314(1):151–158
  38. Gil-Campos M, Canete RR, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr. 2004;23(5):963–974
  39. Hug C, Wang J, Ahmad NS, et al. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A. 2004;101(28):10308–10313
  40. Tsao TS, Murrey HE, Hug C, et al. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem. 2002;277(33):29359–29362
  41. Yamauchi T, Nio Y, Maki T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13(3):332–339
  42. Soares AF, Guichardant M, Cozzone D, et al. Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radic Biol Med. 2005;38(7):882–889
  43. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003;46(12):1594–1603
  44. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439–451
  45. Chen MB, McAinch AJ, Macaulay SL, et al. Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J Clin Endocrinol Metab. 2005;90(6):3665–3672
  46. Inukai K, Nakashima Y, Watanabe M, et al. Regulation of adiponectin receptor gene expression in diabetic mice. Am J Physiol Endocrinol Metab. 2005;288(5):E876–E882
  47. Civitarese AE, Jenkinson CP, Richardson D, et al. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes. Diabetologia. 2004;47(5):816–820
  48. Wang H, Zhang H, Jia Y, et al. Adiponectin receptor 1 gene (ADIPOR1) as a candidate for type 2 diabetes and insulin resistance. Diabetes. 2004;53(8):2132–2136
  49. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002;13(2):84–89
  50. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002;8(7):731–737
  51. Shklyaev S, Aslanidi G, Tennant M, et al. Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci U S A. 2003;100(24):14217–14222
  52. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50(9):2094–2099
  53. Nawrocki AR, Rajala MW, Tomas E, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem. 2006;281(5):2654–2660
  54. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115(5):911–919quiz 920
  55. Goldstein BJ, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004;89(6):2563–2568
  56. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002;277(29):25863–25866
  57. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002;106(22):2767–2770
  58. Kawano T, Saito T, Yasu T, et al. Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. Metabolism. 2005;54(5):653–656
  59. Maahs DM, Ogden LG, Kinney GL, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 2005;111(6):747–753
  60. Iglseder B, Mackevics V, Stadlmayer A, et al. Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: data from the SAPHIR Study. Stroke. 2005;36(12):2577–2582
  61. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest. 2007;117(1):13–23
  62. Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science. 2005;310(5750):996–999
  63. Gourcerol G, Tache Y. Obestatin - a ghrelin-associated peptide that does not hold its promise to suppress food intake and motility. Neurogastroenterol Motil. 2007;19(3):161–165
  64. McKee KK, Tan CP, Palyha OC, et al. Cloning and characterization of two human G protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin receptors. Genomics. 1997;46(3):426–434
  65. Tremblay F, Perreault M, Klaman LD, et al. Normal food intake and body weight in mice lacking the G protein-coupled receptor GPR39. Endocrinology. 2007;148(2):501–506
  66. Holst B, Egerod KL, Schild E, et al. GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology. 2007;148(1):13–20
  67. Jackson VR, Nothacker HP, Civelli O. GPR39 receptor expression in the mouse brain. Neuroreport. 2006;17(8):813–816
  68. de Smet B, Thijs T, Peeters TL, et al. Effect of peripheral obestatin on gastric emptying and intestinal contractility in rodents. Neurogastroenterol Motil. 2007;19(3):211–217
  69. Nogueiras R, Pfluger P, Tovar S, et al. Effects of obestatin on energy balance and growth hormone secretion in rodents. Endocrinology. 2007;148(1):21–26
  70. Gourcerol G, Million M, Adelson DW, et al. Lack of interaction between peripheral injection of CCK and obestatin in the regulation of gastric satiety signaling in rodents. Peptides. 2006;27(11):2811–2819
  71. Qi X, Li L, Yang G, et al. Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2007;66(4):593–597
  72. Butler MG, Bittel DC. Plasma obestatin and ghrelin levels in subjects with Prader-Willi syndrome. Am J Med Genet A. 2007;143(5):415–421
  73. Tatemoto K. Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc Natl Acad Sci U S A. 1982;79(8):2514–2518
  74. Boey D, Sainsbury A, Herzog H. The role of peptide YY in regulating glucose homeostasis. Peptides. 2007;28(2):390–395
  75. Bottcher G, Ahren B, Lundquist I, et al. Peptide YY: intrapancreatic localization and effects on insulin and glucagon secretion in the mouse. Pancreas. 1989;4(3):282–288
  76. Upchurch BH, Aponte GW, Leiter AB. Expression of peptide YY in all four islet cell types in the developing mouse pancreas suggests a common peptide YY-producing progenitor. Development. 1994;120(2):245–252
  77. Grandt D, Schimiczek M, Beglinger C, et al. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept. 1994;51(2):151–159
  78. Degen L, Oesch S, Casanova M, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology. 2005;129(5):1430–1436
  79. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology. 1985;89(5):1070–1077
  80. Beglinger C, Degen L. Gastrointestinal satiety signals in humans–physiologic roles for GLP-1 and PYY?. Physiology & behavior. 2006;89(4):460–464
  81. Parker SL, Carroll BL, Kalra SP, et al. Neuropeptide Y Y2 receptors in hypothalamic neuroendocrine areas are up-regulated by estradiol and decreased by progesterone cotreatment in the ovariectomized rat. Endocrinology. 1996;137(7):2896–2900
  82. Challis BG, Pinnock SB, Coll AP, et al. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochemical and biophysical research communications. 2003;311(4):915–919
  83. Halatchev IG, Ellacott KL, Fan W, et al. Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology. 2004;145(6):2585–2590
  84. Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology. 2005;146(2):879–888
  85. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002;418(6898):650–654
  86. Challis BG, Coll AP, Yeo GS, et al. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). Proceedings of the National Academy of Sciences of the United States of America. 2004;101(13):4695–4700
  87. Moran TH, Smedh U, Kinzig KP, et al. Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. American journal of physiology. 2005;288(2):R384–R388
  88. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. The New England journal of medicine. 2003;349(10):941–948
  89. Pittner RA, Moore CX, Bhavsar SP, et al. Effects of PYY[3-36] in rodent models of diabetes and obesity. International journal of obesity and related metabolic disorders. 2004;28(8):963–971
  90. Moore C, Jodka C, Dang J, Lwin A, Young A. Chronic administration of PYY[3-36] reduces body weight and improves glycaemic control in C57BL/6J mice fed a high fat diet. Diabetes. 2002;51(1):A418–A419
  91. Nieuwenhuizen AG, Karlsson S, Fridolf T, et al. Mechanisms underlying the insulinostatic effect of peptide YY in mouse pancreatic islets. Diabetologia. 1994;37(9):871–878
  92. Boey D, Lin S, Karl T, et al. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia. 2006;49(6):1360–1370
  93. Boey D, Heilbronn L, Sainsbury A, et al. Low serum PYY is linked to insulin resistance in first-degree relatives of subjects with type 2 diabetes. Neuropeptides. 2006;40(5):317–324
  94. Burcelin R, Brunner H, Seydoux J, et al. Increased insulin concentrations and glucose storage in neuropeptide Y Y1 receptor-deficient mice. Peptides. 2001;22(3):421–427
  95. Adrian TE, Sagor GR, Savage AP, et al. Peptide YY kinetics and effects on blood pressure and circulating pancreatic and gastrointestinal hormones and metabolites in man. The Journal of clinical endocrinology and metabolism. 1986;63(4):803–807
  96. Ahren B, Larsson H. Peptide YY does not inhibit glucose-stimulated insulin secretion in humans. European journal of endocrinology / European Federation of Endocrine Societies. 1996;134(3):362–365
  97. Stock S, Leichner P, Wong AC, et al. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. The Journal of clinical endocrinology and metabolism. 2005;90(4):2161–2168
  98. Naslund E, Gryback P, Hellstrom PM, et al. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. International journal of obesity and related metabolic disorders. 1997;21(5):387–392
  99. Alvarez Bartolome M, Borque M, Martinez-Sarmiento J, et al. Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obesity surgery. 2002;12(3):324–327
  100. Inc, N.P.C., Nastech Pharmaceutical Company Reacquires PYY3-36 Nasal Spray for Treatment of Obesity and Will Advance Its Clinical Development. 2006 2nd March 2006 [cited 2007 22nd April 2007]; Available from: http://investor.nastech.com/phoenix.zhtml?c=83674&;p=irol-newsArticle&ID=824413&highlight=.

PII: S1521-690X(07)00065-6

doi: 10.1016/j.beem.2007.07.006

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 4 , Pages 641-655 , December 2007

Article Tools

* Image Usage & Resolution